...Yes, thanks for having us. So it's an exciting time at Ionis for neurology right now. So this first half of the year, the big thing we're doing is getting the trial started for our Angelman program, so the pivotal study. We're getting that for that first half of the year. Then at the end of this year, we have our Alexander's disease program, pivotal study, really. And then next year, we have our Alexander's Disease Phase 2 program reading out. Those are the big upcoming things. In the last year, we've also started four new Phase 1/2 studies in patients for the rest of our neurology franchise. So busy time. Paul Matteis ...
